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Monthly access flow monitoring with increased prophylactic angio-
plasty did not improve fistula patency
Shahin H, Reddy G, Sharafuddin M, et al. Kidney Int 2005;68:2352-61.
Conclusion: A monitoring strategy for autogenous arterial venous
fistulas using an ultrasound dilution technique (UDT) with prophylactic
angioplasty of detected stenoses does not decrease thrombosis rates or
improve fistula patency.
Summary: It is widely believed that regular access monitoring to detect
access stenoses and subsequent prophylactic treatment before thrombosis
will result in overall improved fistula patency. It has, however, been previ-
ously determined that early correction of graft stenoses before thrombosis
did not improve overall graft patency for dialysis access (Kidney Int 2004;
66:390-8). Because the situation may be different for native arteriovenous
fistulas, the authors chose to study their dialysis access monitoring technique
for influence on arteriovenous fistula access thrombosis and failure.
Monthly access monitoring of arteriovenous fistulas using UDT was
instituted at the authors’ institution in 1999. They used a sequential
observational trial design to assess the influence of this strategy on overall
fistula patency. Group 1, a historic control group treated primarily before
1999, had 146 arteriovenous fistulas (50.7% upper arm) andwas followed up
for 259 access years. The group 2 patients had 76 arteriovenous fistulas
(60.5% in the upper arm) and were followed up with UDT monitoring for
123 access years. Referral to angiography and possible angioplasty was based
on clinical criteria for group 1 and a combination of clinical criteria andUDT
flow-monitoring in group 2. Group 2 patients (monitored group) had a
sevenfold increase in angioplasty procedures; however, no improvement was
noted in overall thrombosis rate or cumulative fistula patency.
Comment: Monitoring for development of stenoses in dialysis access
grafts and fistula appears to be unnecessary. This study and the one refer-
enced do not justify sequential monitoring of dialysis access fistulas or grafts,
at least with the monitoring techniques used.
Sildenafil in the treatment of Raynaud’s phenomenon resistant to
vasodilator therapy
Frys R, Shariate K, VonWilmowski H., et al. Circulation 2005;12:2980-85.
Conclusion: Sildenafil is well tolerated and an effective treatment in
patients with secondary Raynaud’s syndrome.
Summary: The authors investigated the effects of sildenafil on capillary
perfusion and symptoms in patients with secondary Raynaud’s syndrome.
The 16 patients in this study received either placebo or 15 mg of sildenafil
twice daily for 4 weeks. The study was designed as a double-blind, fixed-dose
cross-over study. All patients had secondary Raynaud’s syndrome thought to
be resistant to vasodilator therapy. Symptoms were assessed by diary cards
and a 10-point Raynaud’s condition score was used. A laser Doppler
anemometer was used to measure capillary flow velocity in digital nail fold
capillaries. The study was performed during the summer months of 2003.
The frequency of Raynaud’s attacks was significantly lowered while the
patients took sildenafil (35  14 vs 52  18, P  .0064). In addition, the
cumulative attack duration was shorter (581 131 vs 1046 245 minutes,
P  .0038). The mean Raynaud’s condition score was also significantly
lowered with sildenafil (2.2  0.4 vs 3.0  0.5, P  .0386). Sildenafil
increased the mean capillary blood flow velocity in all patients (0.53 0.09
vs 0.13  0.02 mm/s, P  .0004). Two of the 16 patients stopped taking
sildenafil because of adverse effects.
Comment: Sildenafil has a half-life of about 4 hours. Clearly, func-
tional effects exceeded the half-life in this study population. Although
sildenafil has an established effect on erectile dysfunction, it also has been
used successfully in the treatment of pulmonary hypertension and now may
represent the first reasonably effective therapy for secondary Raynaud’s
syndrome.
NXY-059 for acute ischemic stroke
Lees KR, Zivin JA, Ashwood T, et al, and the Stroke-Acute Ischemic NXY
Treatment (SAINT 1) Trial Investigators. N Engl J Med 2006;354:588-
600.
Conclusion: The administration of NXY-0596 hours of the onset of
acute ischemic stroke reduces disability at 90 days but does not significantly
improve other outcomes measures of stroke.
Summary:NXY-059 is an agent that traps free radicals. It has neuron-
protective effects in animal models of stroke. This study tested whether
NXY-059 could reduce disability after acute ischemic strokes in humans.
This was a double-blind, randomized, placebo-controlled trial in which
1722 patients with acute ischemic stroke were randomly assigned to treat-
ment with NXY-059 or placebo. Patients were treated with intravenous
infusions for 72 hours beginning 6 hours from the onset of stroke. The
modified Rankin scale for disability was used as the primary outcome
measure at 90 days.
There were 1699 subjects in the efficacy analysis. NXY-059 improved
overall distribution of scores using the modified Rankin scale compared with
placebo (P .038). Odds ratio for improvement across all categories of the
Rankin scale was 1.2 (95% confidence interval, 1.01 to 1.42). No differences
were noted in serious and nonserious adverse events or mortality comparing
the placebo and NXY-059 groups. NXY-059 did not improve neurologic
function according to the National Institutes of Health Stroke Scale (P 
.86). Also, no differences were observed in the Bartho index in the two
treatment groups (P  .14). In a post hoc analysis of patients who also
received Alteplase, NXY-059 was associated with a lower incidence of
hemorrhagic stroke transformation (P  .001) and a lower incidence of
symptomatic intercranial hemorrhage (P  .036).
Comment: This study shows a modest but statistically significant
benefit of NXY-059 for neuron protection after ischemic stroke. With
NXK-059, and using the modified Rankin scale, 4.4% more patients became
asymptomatic and 3.7% more patients were able to walk without help.
Although other parameters were not statistically significant in this study, this
is the first study in humans to show a neuroprotective effect of drug therapy
for ischemic stroke. Stroke is an extraordinarily disabling condition and has
huge personal and social costs. The number of patients is huge, and
therefore any improvement, even if modest, is progress.
Accuracy of colored duplex ultrasound diagnosis of spontaneous ca-
rotid dissection cause and ischemia
Benninger DH, Georgiadis D, Grandjour J et al. Stroke 2006;37:377-81.
Conclusion: Color duplex ultrasound has high sensitivity and specific-
ity for diagnosis of spontaneous internal carotid artery dissection that causes
neurologic symptoms.
Summary: Carotid duplex ultrasound is frequently used in evaluation
of patients with possible carotid artery dissection. The authors sought to
determine the overall accuracy of color duplex ultrasound to diagnose
spontaneous internal carotid artery dissection in patients with a first episode
of carotid distribution ischemia. Patients with a first episode of carotid
territory stroke, transient ischemic attack, or retinal ischemia underwent an
electrocardiogram (ECG), color duplex ultrasound of the cervical carotid
arteries, and clinical and hematologic examinations. Brain computed tomog-
raphy (CT) scanning was performed in individuals with stroke or transient
ischemic attacks, and echocardiography and 24-hour ECGmonitoring were
used in selective cases. Patients were included if they were 65 years, color
duplex ultrasound showed a probable internal carotid artery dissection
(stenosed or occluded internal carotid artery), or they had no determined
etiology of cerebral ischemia. Included patients also underwent cervical
magnetic resonance imaging (MRI) and MR angiography (MRA) and
possibly cerebral catheter angiography as well. Those who performed the
color duplex ultrasound studies were blinded to the results of the MRI and
angiographic studies.
The study screened 1652 patients, and 177 were included. Internal
carotid artery dissection was diagnosed by carotid duplex ultrasound in 77 of
the 177 patients. The etiology of ischemia was undetermined in the remain-
ing 100 patients. Cervical MRI and MRA indicated 74 of the 177 patients
had spontaneous internal carotid artery dissection. There were three false-
negative and six false-positive color duplex ultrasound examinations. There-
fore, sensitivity, specificity, positive, and negative predictive values for diag-
nosis of spontaneous internal carotid artery dissection using carotid artery
duplex ultrasound in patients with carotid territory ischemic symptoms were
96%, 94%, 92%, and 97%, respectively.
Comment: The very high negative predictive value for excluding
spontaneous carotid artery dissection with color duplex ultrasound essen-
tially allows withholding of treatment for internal carotid artery dissection in
patients in which that diagnosis is suspected but in whom the duplex
ultrasound shows no evidence of dissection. Positive predictive value is also
excellent, but because such patients will be treated with anticoagulation, or
perhaps other interventions, patients in whom internal carotid artery dissec-
tion is diagnosed by duplex should have a confirmatory study before treat-
ment is initiated.
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